Entering text into the input field will update the search result below

Stemline Therapeutics reports Q4 and FY15 results

  • Stemline Therapeutics (NASDAQ:STML) Q4 results: Revenues: $0.2M (+100.0%); R&D Expense: $7.9M (+54.9%); SG&A: $2.6M (+30.0%); Operating Loss: ($10.3M) (-47.1%); Net Loss: ($10.2M) (-47.8%); Loss Per Share: ($0.58) (-9.4%).
  • FY2015 results: Revenues: $0.7M (+133.3%); R&D Expense: $29.5M (+39.2%); SG&A: $8.8M (+8.6%); Operating Loss: ($37.6M) (-29.7%); Net Loss: ($37.2M) (-29.2%); Loss Per Share: ($2.15) (+3.6%); Quick Assets: $46M (-14.8%).
  • No guidance given.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
STML--
Stemline Therapeutics, Inc.